摘要
目的:探讨曲妥珠单抗联合帕妥珠单抗靶向治疗在HER2阳性早期乳腺癌的临床疗效及预后。方法:回顾性分析2018年5月-2019年8月某院收治的通过纳入及排除标准筛选出符合要求的126例HER2阳性乳腺癌患者。依据治疗方式的不同,分为曲妥珠单抗治疗组(对照A组)、帕妥珠单抗治疗组(对照B组)、曲妥珠单抗联合帕妥珠单抗治疗组(试验组)各42例,通过观察比较患者治疗总临床疗效及预后情况。结果:检测HER2、CA153浓度,结果显示治疗后比治疗前的浓度均有明显降低,且治疗后试验组的浓度也明显低于对照A组和对照B组(P<0.05);比较3组临床疗效,结果显示试验组的临床疗效明显优于对照A组、对照B组(P<0.05);比较3组化疗后不良反应的发生情况,试验组比对照A组、对照B组的显著降低(P<0.05)。结论:曲妥珠单抗联合帕妥珠单抗靶向在治疗HER2阳性乳腺癌的疗效及预后较好,安全性较高。
Objective:To investigate the clinical efficacy and prognosis of Trastuzumab combined with Pertuzumab targeted therapy in the treatment of early HER2-positive breast cancer.Methods:A retrospective analysis was performed on 126 patients with HER2-positive breast cancer who were screened out according to the inclusion and exclusion criteria in a hospital from May 2018 to August 2019.According to the different treatment methods,the patients were divided into Trastuzumab treatment group(control group A)(42 cases),Pertuzumab treatment group(control group B)(42 cases),and Trastuzumab combined with Pertuzumab treatment group(experimental group)(42 cases).The total clinical efficacy and prognosis of the patients were observed and compared.Results:The concentrations of CA153 and HER2 were detected,and the results showed that the concentrations after treatment were significantly lower than those before treatment,and the concentrations in the experimental group were significantly lower than those in control group A and Control group B after treatment(P<0.05).The clinical efficacy of the three groups was compared.The results showed that the therapeutic efficacy of the experimental group was significantly better than that of control group A and control group B(P<0.05).Comparing the incidence of adverse reactions after chemotherapy among the three groups,the experimental group was significantly lower than that in control group A and control group B(P<0.05).Conclusion:Trastuzumab combined with Pertuzumab targeted therapy in the treatment of HER2-positive breast cancer has a good efficacy and prognosis,and is relatively safe.
作者
陈璐
关润年
周素珠
Chen Lu;Guan Runnian;Zhou Suzhu(Department of Oncology,Kaiping Central Hospital,Jiangmen 529300;Department of Gastroenterology,Kaiping Central Hospital,Jiangmen 529300)
出处
《数理医药学杂志》
CAS
2022年第7期1030-1032,共3页
Journal of Mathematical Medicine
基金
江门市科技计划项目(编号2021YL10015)
江门市卫生健康局科研立项(编号21A129)。
